Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
VANCOUVER, Washington, Feb. 08, 2019 — CytoDyn Inc. (otc.qb:CYDY), CytoDyn, a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that it will be presenting a company overview at BIO […]
Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of […]
BLA update and major licensing initiatives in cancer and immunology VANCOUVER, Washington, Jan 08, 2019- CytoDyn Inc. (otc.qb:CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
